IRADIMED CORPORATION (IRMD)
NASDAQ: IRMD · Real-Time Price · USD
53.88
+1.80 (3.45%)
Nov 21, 2024, 2:10 PM EST - Market open

Company Description

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally.

It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.

The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories.

It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors.

IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

IRADIMED CORPORATION
IRADIMED CORPORATION logo
Country United States
Founded 1992
IPO Date Jul 16, 2014
Industry Medical Devices
Sector Healthcare
Employees 148
CEO Roger Susi

Contact Details

Address:
1025 Willa Springs Drive
Winter Springs, Florida 32708
United States
Phone 407 677 8022
Website iradimed.com

Stock Details

Ticker Symbol IRMD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001325618
CUSIP Number 46266A109
ISIN Number US46266A1097
Employer ID 73-1408526
SIC Code 3841

Key Executives

Name Position
Roger E. Susi Founder, Chairman, Chief Executive Officer and President
John F. Glenn Chief Financial Officer and Corporate Secretary
Randy Waddell Vice President of Worldwide Sales and Marketing
Chris Williamson Executive Vice President of Continuous Improvement and Information Technology
Matt Garner Controller
Steve Kachelmeyer Vice President of Regulatory Affairs and Quality Assurance
Lynn Neuhardt Vice President of Research and Development

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 6, 2024 144 Filing
Oct 31, 2024 10-Q Quarterly Report
Oct 31, 2024 8-K Current Report
Oct 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Aug 1, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jun 20, 2024 8-K Current Report
Jun 7, 2024 8-K Current Report